content_image/254465.jpg
## Commitments for the acquisition of intangible assets 

The Group has entered into research and development col- laborations and in-license agreements of products and tech- nologies with a number of third parties. These agreements may require the Group to make milestone payments upon the achievement of agreed objectives or when certain conditions are met as defined in the agreements. 

“Research and development milestone payments” represent obligations to pay the amount set out in an individual contract agreement upon achievement of a milestone determined according to the stage of research and development. 

## 37. relateD party transactions 

## (1) Major companies the Group controls 

“Sales milestone payments” represent obligations to pay the amount set out in an individual contract agreement upon achievement of a milestone determined according to the target of sales. 

The amounts shown in the table above represent the maxi- mum payments to be made when all milestones are achieved, and they are undiscounted and not risk adjusted. Since the achievement of the conditions for payment is highly uncertain, it is unlikely that they will all fall due and the amounts of the actual payments may vary considerably from those stated in the table. 

A list of major companies the Group controls is presented in “Principal Subsidiaries and Affiliates”. 

## (2) Compensation of key management personnel 

The table below shows, by the type, the compensation of key management personnel: 

<img src='content_image/254465.jpg'>

Key management personnel consist of 21 people (22 during 2013) including directors, corporate auditors and members of the global management committee. 

## 38. contingent liaBilities 

## Legal Proceedings 

The Group is involved in various claims and legal proceedings of a nature considered common to the pharmaceutical indus- try. These proceedings are generally related to product liability claims, competition and antitrust law, intellectual property matters, employment claims, and government investigations. In general, since litigation and other legal proceedings contain many uncertainties and complex factors, it is often not pos- sible to make reliable judgment regarding the possibility of losses nor to estimate expected financial effect if these matters are decided in a manner that is adverse to the Group. In these cases, disclosures would be made as appropriate, but no provision would be made by the Group. 

Prograf Litigation 

Astellas Pharma US, Inc. (APUS), one of the Company’s indi- rect US subsidiaries, was named as a defendant in 2011 in several separate lawsuits brought by plaintiffs in various federal courts on behalf of themselves and proposed classes of all direct and indirect purchasers of Prograf. These lawsuits involve allegations that under the federal antitrust laws and various state laws, APUS misused the Citizen Petition process for the sole purpose of delaying the approval of generic tacroli- mus by the U.S Food and Drug Administration, thereby injuring the plaintiffs. In June 2011, the US Judicial Panel on Multi- District Litigation ordered that the cases be consolidated before the US District Court for the District of Massachusetts. The case is being vigorously defended. The outcome of this matter or its impact on our financial condition cannot be determined at this time. 

